Semax

Semax is a Russian-developed synthetic peptide that occupies an unusual place in the global peptide landscape: a compound with a real regulatory home (the Russian List of Vital & Essential Drugs since December 2011), a moderately large publication record (more than 200 PubMed-indexed papers), and yet no marketing authorisation anywhere else in the world we cover. The gap between Russian licensed status and Western unapproved status is the central thing to understand about Semax, and it shapes everything from how the evidence reads to how it is sold in our coverage area.

The compound was first described in the early 1990s by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences. The design logic was to take the ACTH(4-7) fragment of adrenocorticotropic hormone, which earlier work had shown carries the cognitive and behavioural effects of full-length ACTH without its adrenal-stimulating action, and add a Pro-Gly-Pro tail to slow enzymatic breakdown. The result is a heptapeptide stable enough to reach the brain via the intranasal route and to produce measurable behavioural effects in rodents.

In Russia, Semax is registered as a prescription nasal spray with indications spanning ischemic stroke recovery, transient ischemic attack, memory and cognitive disorders, optic-nerve disease and immune support. The most-studied Russian clinical indication is acute and post-acute ischemic stroke. A 2018 study by Gusev and colleagues in 110 patients reports increases in plasma BDNF, improvements on the British Medical Research Council motor scale, and gains on the Barthel index of activities of daily living after the standard Russian regimen of two 10-day intranasal courses at 6,000 micrograms per day separated by a 20-day interval. An earlier 1997 paper from the same group described similar findings in the acute period of hemispheric ischemic stroke.

Where the evidence picture gets thinner is in the methodology. The Russian clinical work is largely published in Russian-language journals, the trials are smaller than the multi-thousand-patient datasets that anchor Western drug approvals, and several of the studies are not described in their PubMed abstracts as randomised, placebo-controlled, or double-blind. Mechanistic work is concentrated in a small number of research groups, predominantly at the Institute of Molecular Genetics of the Russian Academy of Sciences and collaborating institutions. None of this makes the Russian findings wrong, but it does mean Semax does not yet have the kind of independent, multi-centre, regulator-grade evidence base that an FDA or EMA approval requires.

The mechanistic story carries real interest. Dolotov and colleagues (2006) report that intranasal Semax at 50 and 250 micrograms per kilogram raises BDNF protein in the rat basal forebrain within three hours, with regional specificity (the cerebellum did not respond). Eremin and colleagues (2005) report rises in striatal serotonin metabolites and amplified dopaminergic response when Semax was combined with amphetamine in rats. A 2025 British Journal of Pharmacology paper extended the picture to the mu-opioid receptor gene Oprm1 in a mouse spinal-cord-injury model. These rodent findings explain why Russian clinicians frame Semax as a neuroprotective and pro-recovery agent, but they do not, on their own, establish a clinical-trial-grade case in humans.

In our coverage area Semax has no marketing authorisation. It is not approved by the FDA in the US, where its legal status is 'unscheduled, not FDA approved'. It is not authorised by the EMA in the EU and EEA; an EMA medicines-search returns no result. It is not authorised by the MHRA in the UK. Online vendors in our coverage area sell Semax nasal sprays and powders into the same grey-market channel that supplies BPC-157 and ipamorelin, sometimes with the original Russian packaging and sometimes as generic 'research peptide' vials.

That grey-market supply situation has the usual implications. There is no batch-level pharmaceutical-grade quality control under any agency we cover, no independent verification that a given vial contains what the label claims, and no recall mechanism if a product turns out to be counterfeit or contaminated. Independent testing of grey-market peptides as a category has repeatedly identified purity, identity and contamination failures; we do not have an independent Semax-specific testing dataset to cite. The Practical considerations section below lists the verifiable quality signals that apply across this product class.

This page is for education and journalism. We do not advise on starting, stopping, dosing, or sourcing Semax, and we do not facilitate the sale of any peptide. Decisions about whether to consider Semax belong with a clinician who knows your medical history. Use the country pages at /regulation/[country]/semax for the jurisdiction-specific picture, and the source list below to read the published Russian clinical and mechanistic work in full.